Veru Inc.

NasdaqCM:VERU Stock Report

Market Cap: US$44.6m

Veru Management

Management criteria checks 3/4

Veru's CEO is Mitch Steiner, appointed in Oct 2016, has a tenure of 9.75 years. total yearly compensation is $1.65M, comprised of 50.7% salary and 49.3% bonuses, including company stock and options. directly owns 4.42% of the company’s shares, worth $1.97M. The average tenure of the management team and the board of directors is 8.3 years and 3.8 years respectively.

Key information

Mitch Steiner

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage50.69%
CEO tenure9.8yrs
CEO ownership4.4%
Management average tenure8.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Analysis Article • Oct 08

Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...
Narrative Update • Aug 15

Aging Trends And FDA Clarity Will Unlock Opportunity

Veru’s future P/E has increased and its net profit margin has declined, indicating deteriorating profitability expectations, but analysts maintain their fair value estimate unchanged at $25.00. What's in the News Veru announced a novel modified release oral formulation for enobosarm in chronic weight loss, achieving target pharmacokinetics and leveraging proprietary delivery technology with positive Phase 2b efficacy and safety data.
Analysis Article • Aug 12

Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge

NasdaqCM:VERU 1 Year Share Price vs Fair Value Explore Veru's Fair Values from the Community and select yours Veru Inc...
Analysis Article • Jun 10

Veru Inc.'s (NASDAQ:VERU) 28% Share Price Surge Not Quite Adding Up

Veru Inc. ( NASDAQ:VERU ) shareholders have had their patience rewarded with a 28% share price jump in the last month...
Seeking Alpha • May 27

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

Summary Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts. Veru's strong Phase 2b data and market potential suggest a substantial upside despite notable risks, making it a classic speculative investment. While current valuation assigns a minimal probability of success, a positive launch could yield peak sales in the billions. Read the full article on Seeking Alpha
User avatar
New Narrative • Apr 04

Enobosarm Phase III And Sabizabulin Tests Will Yield Mixed Prospects

Successful clinical trials indicate potential for regulatory approval and commercialization, enhancing future revenue and earnings.
Analysis Article • Apr 03

Veru Inc.'s (NASDAQ:VERU) 27% Price Boost Is Out Of Tune With Revenues

Those holding Veru Inc. ( NASDAQ:VERU ) shares would be relieved that the share price has rebounded 27% in the last...
Analysis Article • Dec 18

Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 07

Is Veru (NASDAQ:VERU) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jul 17

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...
Analysis Article • May 31

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Veru Inc. ( NASDAQ:VERU ) share price has softened a substantial 35% over the previous 30 days, handing back much...
Analysis Article • Jan 09

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Inc. ( NASDAQ:VERU ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Aug 16

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

The latest analyst coverage could presage a bad day for Veru Inc. ( NASDAQ:VERU ), with the analysts making...
Analysis Article • Apr 17

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Unfortunately for some shareholders, the Veru Inc. ( NASDAQ:VERU ) share price has dived 38% in the last thirty days...
Analysis Article • Feb 14

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

How far off is Veru Inc. ( NASDAQ:VERU ) from its intrinsic value? Using the most recent financial data, we'll take a...

CEO Compensation Analysis

How has Mitch Steiner's remuneration changed compared to Veru's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$14m

Dec 31 2025n/an/a

-US$19m

Sep 30 2025US$2mUS$836k

-US$16m

Jun 30 2025n/an/a

-US$28m

Mar 31 2025n/an/a

-US$29m

Dec 31 2024n/an/a

-US$29m

Sep 30 2024US$2mUS$804k

-US$35m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$62m

Sep 30 2023US$5mUS$866k

-US$93m

Jun 30 2023n/an/a

-US$126m

Mar 31 2023n/an/a

-US$136m

Dec 31 2022n/an/a

-US$116m

Sep 30 2022US$6mUS$761k

-US$84m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021n/an/a

-US$16m

Sep 30 2021US$2mUS$618k

US$7m

Jun 30 2021n/an/a

-US$144k

Mar 31 2021n/an/a

-US$476k

Dec 31 2020n/an/a

US$2m

Sep 30 2020US$1mUS$502k

-US$19m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019n/an/a

-US$13m

Sep 30 2019US$800kUS$392k

-US$12m

Compensation vs Market: Mitch's total compensation ($USD1.65M) is above average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.

CEO

Mitch Steiner (65 yo)

9.8yrs
Tenure
US$1,649,663
Compensation

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

Leadership Team

NamePositionTenureCompensationOwnership
Mitchell Steiner
Chairman9.8yrsUS$1.65m4.42%
$ 2.0m
Harry Fisch
Vice Chairman & Chief Corporate Officer9.8yrsUS$769.42k4.99%
$ 2.2m
K. Barnette
Chief Scientific Officer7.8yrsUS$941.01k0.0031%
$ 1.4k
Michele Greco
CFO & Chief Administrative Officer8.6yrsUS$1.55m0.060%
$ 26.7k
Samuel Fisch
Executive Director of Investor Relations & Corporate Communications7.3yrsno datano data
Philip Greenberg
Executive VPless than a yearno datano data
Kevin Gilbert
Executive Vice President of Corporate Development9.5yrsno datano data
Martin Tayler
Executive Vice President of FC2 Global Operationsno dataUS$193.01kno data
Domingo Rodriguez
Executive Vice President of Global Clinical Operations8.3yrsno datano data
Gary Bird
Executive Vice President of Quality & Regulatory Affairs7.4yrsno datano data
Alistair Rawson
Executive Vice President of Operations - GPS Salesno datano datano data
Aaftine Antillon
Senior Vice President of Financeno datano datano data
8.3yrs
Average Tenure
64.5yo
Average Age

Experienced Management: VERU's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mitchell Steiner
Chairman9.8yrsUS$1.65m4.42%
$ 2.0m
Harry Fisch
Vice Chairman & Chief Corporate Officer9.8yrsUS$769.42k4.99%
$ 2.2m
Louis Aronne
Chief Medical Advisor & Member of the Scientific Advisory Board2.3yrsno datano data
Andrew Love
Board Observer9.8yrsno datano data
Adrian Dobs
Member of Scientific Advisory Board2.4yrsno datano data
William Evans
Member of Scientific Advisory Board2.4yrsno datano data
Michael Rankowitz
Independent Director8.3yrsUS$61.22k0.16%
$ 69.5k
Xiaoqin Lu
Independent Director5.2yrsUS$58.04k0.0061%
$ 2.7k
Caroline Apovian
Member of Scientific Advisory Board2.4yrsno datano data
Loren Katzovitz
Independent Director1.9yrsUS$42.76k0.14%
$ 62.3k
Grace Hyun
Independent Director5.9yrsUS$51.46k0.0092%
$ 4.1k
Shalender Bhasin
Member of Scientific Advisory Board2.4yrsno datano data
3.8yrs
Average Tenure
66yo
Average Age

Experienced Board: VERU's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 14:06
End of Day Share Price 2026/07/13 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veru Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Yuchen DingJefferies LLC
Leland GershellOppenheimer & Co. Inc.